News Industry News Boston Scientific Initiates Trial Comparing Left Atrial Appendage Closure to Direct Oral Anticoagulants for Stroke Risk Reduction Post-AFib Ablation May 22, 2019
News Industry News New Real-World Analysis Finds Lower Risk of Major Bleeding and Similar Risk of Stroke with Standard Dose of Pradaxa® Compared to Rivaroxaban in NVAF Patients Newly Initiating Treatment January 29, 2018
News Industry News CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®) September 25, 2015